Transfusion and Apheresis Science最新文献

{"title":"Passenger lymphocyte syndrome: A rare cause of post-transplant hemolysis following minor ABO-incompatible living donor liver transplantation","authors":"Thibault Lavalleye ,&nbsp;Corentin Streel ,&nbsp;Olga Ciccarelli ,&nbsp;Catherine de Magnée ,&nbsp;Véronique Deneys","doi":"10.1016/j.transci.2025.104264","DOIUrl":"10.1016/j.transci.2025.104264","url":null,"abstract":"<div><div>Passenger lymphocyte syndrome (PLS) is a rare cause of sudden-onset hemolytic anemia 1–3 weeks after hematopoietic stem cell or solid organ transplantation. Early recognition is key as it informs transfusion protocols. Diagnostic is based on the detection of theses antibodies using direct antiglobulin test (DAT), elution and titration. When treatment is needed, antigen-negative transfusion is sufficient in most cases. Severe cases management includes glucocorticoids, rituximab, plasmapheresis and intravenous immunoglobulins. We report two cases of PLS in living donor liver transplant with minor ABO incompatibility. Both patients developed symptomatic anemia and required red blood cell transfusions, as well as escalation of immunosuppressive therapy.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 6","pages":"Article 104264"},"PeriodicalIF":1.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145361769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful multimodal intensive care management including early plasmapheresis and granulocyte colony stimulating factor in severe colchicine poisoning: A case report","authors":"Gizem Demir Şenoğlu ,&nbsp;Özlem Ersoy Karka ,&nbsp;Yavuz Demiraran ,&nbsp;Birgül Oneç","doi":"10.1016/j.transci.2025.104280","DOIUrl":"10.1016/j.transci.2025.104280","url":null,"abstract":"<div><div>Colchicine is a narrow therapeutic index drug widely used in the treatment of inflammatory diseases such as acute gout attacks and Familial Mediterranean Fever (FMF). In case of overdose, the risk of toxicity is high and can rapidly lead to multiple organ failure. The lack of an antidote for colchicine toxicity continues the search for a definitive treatment. We present a case of severe colchicine toxicity managed successfully with early initiation of therapeutic plasma exchange (TPE), intensive supportive care including noninvasive ventilation, hemodynamic stabilization, electrolyte management, and granulocyte colony- stimulating factor (G-CSF) therapy. This multimodal intensive care approach resulted in complete recovery.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 6","pages":"Article 104280"},"PeriodicalIF":1.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145394715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality in transfusion medicine: How to master and sustain","authors":"Cees Th. Smit Sibinga","doi":"10.1016/j.transci.2025.104276","DOIUrl":"10.1016/j.transci.2025.104276","url":null,"abstract":"<div><div>The vein-to-vein transfusion chain consists of two distinct elements –</div><div><ul><li><span>1)</span><span><div>the procurement part, focused on the manufacturing of safe, effective and quality-assured blood products from blood donated by (preferably regular) voluntary blood donors;</div></span></li><li><span>2)</span><span><div>the clinical decision making, prescription and use of blood components in the hospitals.</div></span></li></ul></div><div>To allow consistent preparation and use of blood components that are safe and clinically efficacious, an appropriate and transparent quality system should be put in place that covers both the management, as well as the technical operations of facilities involved in the chain and leads to the development of a quality culture and sustained stewardship in transfusion medicine. This article describes and discusses the different managerial and operational systems available and their applicability in transfusion medicine; how to master and sustain.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 6","pages":"Article 104276"},"PeriodicalIF":1.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145460473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mob-Marly: A Latin American experience in hematopoietic stem cell mobilization for autologous transplantation","authors":"Óscar Peña ,&nbsp;Licet Villamizar ,&nbsp;Paola Charry ,&nbsp;Tatiana Camargo ,&nbsp;Enrique Pedraza ,&nbsp;Joan Cid","doi":"10.1016/j.transci.2025.104244","DOIUrl":"10.1016/j.transci.2025.104244","url":null,"abstract":"<div><h3>Background</h3><div>Hematopoietic stem cell (HSC) mobilization is a critical step in autologous transplantation for patients with multiple myeloma and lymphoma. While several risk factors for mobilization failure have been identified, real-world data from Latin America remain limited. This study aimed to describe mobilization outcomes and associated factors in a transplant center in Colombia.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study including patients with multiple myeloma or lymphoma who initiated HSC mobilization between 2019 and 2023 at Clínica de Marly in Bogotá, Colombia. The primary outcome was mobilization success, defined as the collection of at least 2 × 10⁶ CD34⁺ cells/kg. We analyzed clinical, treatment-related, and laboratory variables using univariate and multivariate logistic regression to identify factors associated with mobilization success or failure.</div></div><div><h3>Results</h3><div>A total of 414 patients were included; the overall mobilization success rate was 86.7 %. In multivariate analysis, previous mobilization failure (OR 0.035, p &lt; 0.001), age ≥ 65 years (OR 0.94, p = 0.003), and lymphoma diagnosis (OR 0.39, p = 0.02) were independently associated with mobilization failure. CD34⁺ counts on days + 4 and + 5 were strong predictors of successful mobilization, with thresholds of &gt; 10 × 10⁶/L and &gt; 20 × 10⁶/L, respectively. Currently, at our center, the standard mobilization regimen consists of filgrastim 10 µg/kg/day for five days, with just-in-time plerixafor administered based on CD34⁺ monitoring results.</div></div><div><h3>Conclusion</h3><div>Hematopoietic stem cell (HSC) mobilization remains a multifactorial challenge influenced by patient-, disease-, and treatment-related factors. Our findings underscore the importance of early identification of poor mobilizers and support the use of CD34⁺ monitoring and just-in-time plerixafor as effective strategies to optimize mobilization outcomes, particularly in resource-limited settings.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 6","pages":"Article 104244"},"PeriodicalIF":1.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144922595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of anticoagulant used for peripheral blood collection on NK cell yield, function, and proliferation","authors":"Catherine A. Cash ,&nbsp;Dean A. Lee","doi":"10.1016/j.transci.2025.104253","DOIUrl":"10.1016/j.transci.2025.104253","url":null,"abstract":"<div><div>Natural killer (NK) cells are under investigation for cellular immunotherapy of cancer, infectious diseases, and autoimmunity. The collection of autologous or allogeneic starting material for the expansion of NK cells - whether whole blood, cord blood, or leukocyte apheresis - requires the use of anticoagulants. Heparin and acid citrate dextrose A (ACD-A) are most commonly used for collection, but their impact on NK cells has not been clearly described. As functional impairment has been described for irreversible calcium chelation with EDTA, we hypothesized that prolonged calcium chelation by ACD-A might also have an adverse impact on NK cell health, particularly with prolonged exposure. To test this hypothesis, peripheral blood was collected as paired samples in heparin and in ACD-A, stored for 24 h at room temperature, and then tested for viable NK cell yield and proliferative capacity for 2 weeks under <em>ex vivo</em> expansion. Both conditions yielded similar viability and T/NK cell content after initial isolation. However, compared to ACD-A-treated blood, heparin-treated blood provided a mean 23 % higher initial yield of NK cells (p = 0.03) and a non-significant trend toward greater fold expansion, which resulted in 60 % higher overall yield after expansion (p = 0.048). These data suggest that both ACD-A and heparin can be used for NK cell collection, but that heparin may be the preferred anticoagulant if there is an expected delay in the product processing such as a pause for overnight testing or shipping. Process development for cellular therapeutics should assess the impact of anticoagulant used for cell collection.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 6","pages":"Article 104253"},"PeriodicalIF":1.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145060922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RBC deformability and clinical relevance in transfusion recipients","authors":"Mahsa Yazdanbakhsh ,&nbsp;Celina Phan ,&nbsp;Pratham Patel ,&nbsp;Ethan Simpson ,&nbsp;Kaitlyn Wingnean ,&nbsp;Jason P. Acker","doi":"10.1016/j.transci.2025.104278","DOIUrl":"10.1016/j.transci.2025.104278","url":null,"abstract":"<div><div>Red blood cell (RBC) deformability—the ability of RBCs to change shape—is crucial for their passage through microvessels and effective oxygen delivery. Deformability depends on the cell’s surface area-to-volume ratio, internal viscosity, and membrane elasticity. Deformability is assessed using single-cell methods like micropipette aspiration and bulk flow techniques such as ektacytometry. RBC deformability decreases during cold storage due to biochemical and structural changes known as storage lesions. Additional processes like cryopreservation and irradiation further impair the deformability of stored RBCs. Donor factors, including age, sex, lifestyle, and health, also influence RBC mechanical properties, affecting transfusion outcomes. Clinically, transfusing RBCs with reduced deformability is linked to impaired microvascular flow, decreased oxygen delivery, and faster clearance from the circulation, especially in patients with chronic or inflammatory conditions. Despite its importance, deformability testing is not yet standard in transfusion practice. New technologies offer potential for routine deformability assessment which could improve transfusion outcomes by optimizing RBC quality and matching units to patient needs.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 6","pages":"Article 104278"},"PeriodicalIF":1.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145361772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of apheresis devices","authors":"Zdravko Kvržić","doi":"10.1016/j.transci.2025.104271","DOIUrl":"10.1016/j.transci.2025.104271","url":null,"abstract":"","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 6","pages":"Article 104271"},"PeriodicalIF":1.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145402379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Repurposing surplus plasma and expired platelets into useful biotherapies","authors":"Hadi Goubran ,&nbsp;Jay Epstein ,&nbsp;Thierry Burnouf","doi":"10.1016/j.transci.2025.104277","DOIUrl":"10.1016/j.transci.2025.104277","url":null,"abstract":"<div><div>Substantial volumes of plasma and platelet concentrates are discarded annually when they exceed transfusion needs or reach the end of their shelf life. Rather than treating these surplus units as waste, blood establishments can repurpose them into safe, useful biotherapies. This updated perspective article highlights practical approaches to valorize surplus blood and plasma through preparation of pathogen-reduced cryoprecipitate and cryoprecipitate-reduced plasma; serum eye drops; mini-pool immunoglobulins; and contract fractionation to produce plasma derived medicinal products (PDMPs, e.g., immunoglobulins, clotting factors, and albumin), complemented, where feasible, by commercially sourced PDMPs or alternative recombinant products. Concurrent plasma from plateletpheresis provides an additional underutilized source of plasma potentially suitable for fractionation. Similarly, expired platelet concentrates can be converted into human platelet lysates, growth-factor concentrates, or extracellular vesicles for cell therapy applications and advanced regenerative medicine. Implementation of these developments requires strict alignment with international quality standards, appropriate microbial and viral safety measures, and clear regulatory oversight. Importantly, the clinical use of allogeneic blood products, especially emerging platelet-derived preparations, should be reserved for justified and proven indications. Repurposing surplus plasma and platelets is not only a way to reduce waste, but also an opportunity for blood establishments to play a driving role in the delivery of safe, evidence-based biotherapies that augment and expand treatment options, improve patient outcomes, and foster national strategic independence, sustainability and resilience in access to current and emerging biotherapies.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 6","pages":"Article 104277"},"PeriodicalIF":1.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145356578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends and determinants of red blood cell transfusion in liver cancer surgeries in Korea (2012–2020)","authors":"Seonju Kim ,&nbsp;Junghyun Yoon ,&nbsp;Sunghee Hong ,&nbsp;Yunkyung Jung ,&nbsp;Dongho Choi ,&nbsp;Gyeonggeun Lee ,&nbsp;Gyeongsik Kim ,&nbsp;Boyoung Park","doi":"10.1016/j.transci.2025.104259","DOIUrl":"10.1016/j.transci.2025.104259","url":null,"abstract":"<div><div>This study detailed RBC transfusion trends in liver cancer surgeries in Korea from 2012 to 2020, identifying a significant decline in transfusion rates and key factors like surgical method and timing. The importance of this research is its potential to guide optimal patient blood management strategies, emphasizing considerations necessary for improving transfusion practices and patient outcomes in liver cancer surgeries.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 6","pages":"Article 104259"},"PeriodicalIF":1.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145266393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-volume plasma exchange for acute liver failure: A retrospective study of 45 patients in Vietnam","authors":"Nguyen Dang Duc ,&nbsp;Lam Nguyen Hong Anh ,&nbsp;Lam Nguyen Hong Khanh ,&nbsp;Nguyen Dang Bach","doi":"10.1016/j.transci.2025.104281","DOIUrl":"10.1016/j.transci.2025.104281","url":null,"abstract":"<div><div>High-volume plasma exchange (HVP) has been proposed as an adjunctive therapy for acute liver failure (ALF), with prior randomized trials showing improved transplant-free survival. We conducted a retrospective, single-center study of 45 acute liver failure patients who received HVP at the Poison Control Center, Bach Mai Hospital, Hanoi, Vietnam, to describe the 28-day outcomes, treatment-related complications, and factors associated with survival. Patient variables including age, gender, etiology, survival at 28 days, international normalized ratio (INR), plasma volume per exchange, hospital stay, and complications were collected. Data were analyzed using SPSS 27. Descriptive statistics (mean ± SD, median ± IQR) were applied, and INR was compared between survivors and non-survivors using t-test (p &lt; 0.05). The mean age was 47 ± 16 years; 24 (53.3 %) were male. Leading etiologies were traditional medicine/herbal use 22(48.9 %), paracetamol 9(20.0 %), and other causes 14(31.1 %). The 28-day survival rate was 53.3 % (24/45). Mean INR at admission was 3.30 ± 2.45; survivors had lower INR (2.67) than non-survivors (4.02), though not statistically significant (p = 0.082). Each HVP used a mean plasma volume of 8.27 ± 1.19 L. Mean hospital stay was 9.8 ± 7.3 days. Complications included anaphylaxis/allergic reactions in 13 (28.9 %) and bleeding in 2 (4.4 %), while no complications occurred in 30 (66.7 %) patients. In this cohort, HVP (mean 8.27 L per exchange) was associated with a 28-day survival rate of 53.3 %, comparable to that reported in previous studies, though causality cannot be inferred due to the absence of a control group. Our findings highlight the high prevalence of ALF from traditional medicine in Vietnam and support the need for prospective, multicenter studies to refine prognostic factors and optimize HVP protocols. These results support the use of HVP as a feasible and safe supportive therapy in resource-limited settings.Limitationsin our study include the retrospective design, single-center setting, small sample size, and absence of a control group. This study was approved by the Institutional Ethics Committee of Bach Mai Hospital, Hanoi, Vietnam.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 6","pages":"Article 104281"},"PeriodicalIF":1.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145446196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}